ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC)

“…A phase II study of ABX-EGF monotherapy in patients with pretreated metastatic colorectal cancer has shown encouraging activity data; 15 of 148 patients (10.1%) had a confirmed partial response at the expense of low (mainly skin) toxicity [25]. Crawford et al [26] have recently presented the preliminary results of a two-part phase II trial of ABX-EGF in combination with paclitaxel and carboplatin in advanced NSCLC. Nineteen patients were enrolled into three ABX-EGF cohorts.…”

Section: Abx-egfmentioning

confidence: 97%

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors

Caponigro

Formato

Caraglia

et al. 2005

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Whether this is associated with diminished antitumor efficacy is not clear. In a phase 2 trial in advanced NSCLC, the addition of panitumumab to carboplatin (generic, Spectrum, Irvine, CA, USA) and paclitaxel (Taxol, Bristol-Myers Squibb, Princeton, NJ, USA) chemotherapy did not appear to provide a benefit with regard to the primary endpoint of disease progression (4.2 months for the panitumumab arm vs. 5.3 months for the chemotherapy-alone arm; P=0.55) [27].…”

Section: Mechanisms Of Egfr-mediated Tumor Resistancementioning

confidence: 99%

Cetuximab in combination therapy: from bench to clinic

Gerber

Choy

2010

Cancer Metastasis Rev

View full text Add to dashboard Cite

Cetuximab, a chimeric IgG(1) monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.

show abstract

ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC)

Cited by 19 publications

References 0 publications

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors

Cetuximab in combination therapy: from bench to clinic

Contact Info

Product

Resources

About